Deep Dive 2025 | AI-Driven Enzyme Discovery, U.S. Expansion, and Growth Strategy
Michael Schneiders, CFO of BRAIN Biotech AG, adresses the seven most frequently asked questions from institutional investors, providing insights, perspectives, and a forward-looking outlook on topics ranging from AI-powered enzyme discovery and U.S. expansion to M&A strategy and the commercial pipeline within the BRAINBioIncubator portfolio.
BRAIN Biotech AG Financial Results 9M 2024 / 25
CFO Michael Schneiders: Strong Core Growth & BioIncubator Innovations
BRAIN Biotech AG Elevator Pitch 2025 | Strategie und Visionen
CFO Michael Schneiders: Strategie und Visionen der BRAIN Biotech AG
(Aufnahmedatum: 4. Juni 2025)
BRAIN Biotech AG Financial Results H1 2024/25
CFO Michael Schneiders: Financial Results H1 2024/25 | Innovation Momentum and Strategic Focus
BRAIN Biotech AG Financial Results Q1 2024/25
CFO Michael Schneiders: Financial Results Q1 2024/25 | Growth, Innovation & Outlook
Finanzjahr 2023/24
BRAIN Biotech AG Financial Results FY 2023/24
CFO Michael Schneiders: Financial Performance and Growth Strategy of BRAIN Biotech AG